Atrium Therapeutics, Inc.
About Atrium Therapeutics, Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $19.6M
- Net income
- -$16.6M
- Total assets
- $292.4M
- Market cap
- $201.8M
- Operating margin
- -3977.3%
- Net margin
- -3650.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $18.8M
- Operating expenses
- $764.7M
- Operating income
- -$745.9M
- Income tax
- $0
- Net income
- -$684.6M
- EPS (basic)
- $-4.97
- EPS (diluted)
- $-4.97
Balance sheet
- Total assets
- $2.0B
- Current assets
- $1.8B
- Total liabilities
- $269.4M
- Current liabilities
- $195.4M
- Shareholders’ equity
- $1.7B
Cash flow
- Operating cash flow
- -$650.4M
- Investing cash flow
- -$38.0M
- Financing cash flow
- $851.0M
- Net cash flow
- $162.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $201.8M
- EPS (diluted)
- $-4.97
- Shares outstanding
- 17.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 27, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $16.6M in FY2026.
- Revenue grew 176% from FY2020 to FY2025.
- Trading 84% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Atrium Therapeutics, Inc..
Write a review
News about Atrium Therapeutics, Inc.
News & sentiment via Polygon.io
